What Clinics Won't Tell You About Weight Loss
The South Florida Trim Clinic Podcast
Real talk about GLP-1 therapy, food noise, the gray market, and everything the weight loss industry doesn't want you asking. No fluff. No filter.
South Florida
Trim Clinic
What Clinics Won't Tell You About Weight Loss
About the Show
The conversations most clinics won't have with you
The South Florida Trim Clinic podcast covers the topics the weight loss industry glosses over — where GLP-1 medications actually come from, why food noise is a biological reality not a character flaw, how ultra-processed foods are engineered to make dieting nearly impossible, and how to access real medical care without paying for celebrity marketing.
If you have questions your clinic isn't answering, this show is for you.
Episodes
What we cover
Each episode digs into a topic that matters to real patients — straightforward, honest, and without the sales pitch.
What Clinics Won't Tell You About GLP-1 Medications
The questions most clinics dodge — what's really in the vials, where it's compounded, and why source matters more than price.
Food Noise Is Real — And It's Not Your Fault
Why hunger feels relentless for some people, what GLP-1 therapy actually does to appetite signals, and how to finally quiet the loop.
Gray Market Weight Loss: The Hidden Danger
The difference between FDA-registered compounding pharmacies and offshore suppliers — and why it matters for your safety.
Ultra-Processed Foods and Why Diets Keep Failing
How the modern food environment is engineered to override willpower — and what the science actually says about processed food and weight.
The Truth About Celebrity Weight Loss Programs
Why household-name brands charge more for less — and how a no-celebrity-budget model can actually serve patients better.
Making Medical Weight Loss Affordable
How to access medically supervised treatment without insurance, without a waiting room, and without paying for things you don't need.
Subscribe so you never miss an episode
New episodes drop regularly. Follow the show on Amazon Music and get notified when we release fresh content on GLP-1 therapy, weight loss science, nutrition, and patient education.
MEDICAL SOURCES & FURTHER READING
These sources address the topics identified below. They provide general education, not individualized medical advice, a clinic endorsement or a prediction of your results. Prescription treatment requires evaluation by a licensed provider; eligibility, medication and dosing depend on individual circumstances.
NIH — National Institute of Diabetes and Digestive and Kidney Diseases
Prescription Medications to Treat Overweight & ObesityWeight-management medication eligibility, appetite, lifestyle support and individualized treatment decisions.
Mayo Clinic
Prescription weight-loss drugsPotential benefits, side effects, eligibility and the role of ongoing professional care.
Cleveland Clinic
GLP-1 AgonistsGLP-1 mechanisms, gastrointestinal effects, risks and when to contact a healthcare provider.
U.S. Food and Drug Administration
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossLack of FDA approval for compounded drugs, dosing errors, quality concerns and limits on compounding.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding, Rachel L. Batterham, Salvatore Calanna, et al.; STEP 1 Study Group · New England Journal of Medicine · 2021
Research published in the New England Journal of Medicine reported greater mean weight reduction with semaglutide plus lifestyle intervention than with placebo in the studied population. This was not a study of Sarasota Trim Clinic or compounded medication, and individual results vary.
- Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.; SURMOUNT-1 Investigators · New England Journal of Medicine · 2022
Research published in the New England Journal of Medicine reported weight reduction across the tirzepatide groups during a 72-week trial with lifestyle intervention. Results depended on the trial regimen and population, do not establish compounded-product equivalence, and are not a clinic outcome or a guarantee.